Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis
Husam Ghanim, Sanaa Abuaysheh, Jeanne Hejna, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 4, pp. e1056-e1063
Open Access | Times Cited: 154

Showing 51-75 of 154 citing articles:

New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling
Yang Chen, Daoquan Peng
International Immunopharmacology (2023) Vol. 118, pp. 110072-110072
Open Access | Times Cited: 12
Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
Veronika A. Myasoedova, Michele Bozzi, Vincenza Valerio, et al.
Antioxidants (2023) Vol. 13, Iss. 1, pp. 16-16
Open Access | Times Cited: 12
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
Akihiko Koshino, Brendon L. Neuen, Niels Jongs, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 11
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial
Mikhail Kosiborod, Sheryl L. Windsor, Orly Vardeny, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 10, pp. 725-734
Open Access | Times Cited: 4
A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease
Lucia Del Vecchio, Angelo Beretta, Carlo Jovane, et al.
Drugs (2021) Vol. 81, Iss. 13, pp. 1491-1511
Closed Access | Times Cited: 26
The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection
Pierre Delanaye, André Scheen
Diabetes & Metabolism (2021) Vol. 47, Iss. 6, pp. 101285-101285
Closed Access | Times Cited: 26
Increase in hematocrit with SGLT-2 inhibitors - Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia?
Preethika Ekanayake, Sunder Mudaliar
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2022) Vol. 17, Iss. 2, pp. 102702-102702
Closed Access | Times Cited: 17
SGLT2 inhibitor dapagliflozin alleviates intramyocardial hemorrhage and adverse ventricular remodeling via suppressing hepcidin in myocardial ischemia-reperfusion injury
Rundu Chen, Yingqian Zhang, Haoran Zhang, et al.
European Journal of Pharmacology (2023) Vol. 950, pp. 175729-175729
Closed Access | Times Cited: 10
Personalized approach in the management of women with heart failure with preserved ejection fraction and carbohydrate metabolism disorders
Lileia Petrovska, Iryna Kostitska, Taras Petrovskyy, et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) (2025) Vol. 20, Iss. 8, pp. 622-632
Open Access
Advances in SGLT-2 Inhibitors in the Treatment of Diabetic Nephropathy
维 邹
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 886-893
Closed Access
Relationship of dietary intake and eating behaviors with glycemic control and body weight under long-term treatment with dapagliflozin: an exploratory prospective study
Hisashi Yokomizo, Daiji Kawanami, Noriyuki Sonoda, et al.
Diabetology International (2025)
Closed Access
SGLT2 Inhibitors Increase Hemoglobin and Hematocrit Levels in Patients With Chronic Kidney Disease: A Systematic Review and Meta‐Analysis
Hye Duck Choi, Seung Woo Lee
Journal of Clinical Pharmacy and Therapeutics (2025) Vol. 2025, Iss. 1
Open Access
The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus—A pilot study
Petra Meliš, Marko Lucijanić, Bojana Kranjčec, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis
Nikita Ermolaev, Robin Willixhofer, Christoph Krall, et al.
Reviews in Cardiovascular Medicine (2025) Vol. 26, Iss. 3
Open Access
SGLT2 Inhibitors in Heart Failure
Kieran F. Docherty
Journal of the American College of Cardiology (2025) Vol. 85, Iss. 18, pp. 1771-1773
Closed Access
Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure
João Pedro Ferreira, Stefan D. Anker, Javed Butler, et al.
Journal of the American College of Cardiology (2025) Vol. 85, Iss. 18, pp. 1757-1770
Closed Access
JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy
Naseema Gangat, Natasha Szuber, Hassan B. Alkhateeb, et al.
Blood (2021) Vol. 138, Iss. 26, pp. 2886-2889
Open Access | Times Cited: 22
The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure
Petter Bjornstad, Peter J. Greasley, David C. Wheeler, et al.
Journal of Cardiac Failure (2021) Vol. 27, Iss. 12, pp. 1447-1455
Open Access | Times Cited: 21
The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest
Dimitrios Patoulias, Nikolaos Fragakis, Manfredi Rizzo
Life (2022) Vol. 12, Iss. 12, pp. 2062-2062
Open Access | Times Cited: 15
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
Anjay Rastogi, James L. Januzzi
Journal of Clinical Medicine (2023) Vol. 12, Iss. 8, pp. 2824-2824
Open Access | Times Cited: 9
Role of Glycosuria in SGLT2 Inhibitor–Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial
Ele Ferrannini, Anna Solini, Simona Baldi, et al.
Diabetes (2023) Vol. 73, Iss. 2, pp. 250-259
Open Access | Times Cited: 8
SGLT2 inhibitors, intrarenal hypoxia and the diabetic kidney: insights into pathophysiological concepts and current evidence
Georgios S. Papaetis
Archives of Medical Science - Atherosclerotic Diseases (2024) Vol. 8, Iss. 1, pp. 155-168
Open Access | Times Cited: 3
Effect of SGLT2 inhibitors on anemia and their possible clinical implications
Aleix Cases, Secundino Cigarrán, José Luis Górriz, et al.
Nefrología (English Edition) (2024) Vol. 44, Iss. 2, pp. 165-172
Open Access | Times Cited: 3
Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions
Adriana Castello Costa Girardi, Juliano Z. Polidoro, Paulo C. Castro, et al.
AJP Cell Physiology (2024) Vol. 327, Iss. 3, pp. C525-C544
Closed Access | Times Cited: 3
Sodium-Glucose Cotransporter 2 Inhibitors Improve Body Composition by Increasing the Skeletal Muscle Mass/Fat Mass Ratio in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
Sara Volpe, Alfredo Vozza, Giuseppe Lisco, et al.
Nutrients (2024) Vol. 16, Iss. 22, pp. 3841-3841
Open Access | Times Cited: 3

Scroll to top